20:56 , Apr 11, 2019 |  BC Week In Review  |  Company News

Aveo could lose Fotivda's EU approval if August analysis confirms negative OS trend

EMA's CHMP will consider regulatory action should an interim overall survival analysis of Fotivda tivozanib, planned for August, confirms the negative OS trend that Aveo disclosed in an April 3 SEC filing. The European Commission...
01:32 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

Aveo shares drop with uncertainty of NDA submission for Fotivda

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $1.07 (60%) to $0.70 on Jan. 31 after the company said it will not submit an NDA to FDA based on preliminary survival data from the Phase III TIVO-3 trial...
19:23 , Jan 31, 2019 |  BC Extra  |  Company News

Aveo shares drop with uncertainty of NDA submission for Fotivda

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $1.07 (60%) to $0.70 Thursday after the company said it will not submit an NDA to FDA based on preliminary survival data from the Phase III TIVO-3 trial for Fotivda...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:18 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months despite reporting preliminary data showing no overall survival benefit for Fotivda tivozanib as a...
23:22 , Nov 6, 2018 |  BC Extra  |  Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

Despite announcing plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months, Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $0.51 (20%) to $2.03 on Tuesday after reporting preliminary data late...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
16:39 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Aveo drops on delay for Phase III tvozanib readout

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $0.69 (24%) to $2.16 on July 17 after delaying for at least the second time an expected readout from a Phase III trial of tivozanib to treat advanced renal cell...
18:15 , Jul 17, 2018 |  BC Extra  |  Clinical News

Aveo drops on delay for Phase III tivozanib readout

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $0.69 (24%) to $2.16 on Tuesday after delaying for at least the second time an expected readout from a Phase III trial of tivozanib to treat advanced renal cell carcinoma...
20:00 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (NYSE:NVS; SIX:NOVN) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights...